domestic growth by a wide margin
Semaglutide activates only GLP-1 receptors, while tirzepatide activates both GLP-1 and GIP receptors
The gap between trial and real-world tirzepatide vs semaglutide outcomes comes mostly from discontinuation and under-titration: only 25.9% of tirzepatide users reach 15 mg in practice, versus 83.5% of semaglutide users reaching 2.4 mg in the trial
Furthermore, compelling evidence implicates this local, brainstem-derived GLP-1, rather than gut-derived GLP-1, as a principal modulator of physiological GLP-1R dependent signals that regulate appetite and body weight (Drucker and Asa, 1988
This treatment is suitable for those committed to a healthier lifestyle and looking for a medically-backed solution
Topiramate can cause cognitive slowing, word-finding difficulty, and in some patients mood changes including depression